Reporter brief
RCT protocol for weekly rapamycin derivatives in older adults; results not yet reported
What happened
RAP PAC is a randomised trial designed to identify safe weekly doses of sirolimus or everolimus in adults aged 55-89 without overt chronic disease. Participants receive 6 weeks of treatment at 5, 10, or 15 mg once weekly. This is a protocol description; no efficacy or safety outcomes have been reported.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Participants aged 55-89 years old that are free of overt chronic diseases
- Design
- Rct
- Sample
- —
- Journal
- University of Wisconsin, Madison
- Published
- May 28, 2026
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.